Compare NKTX & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKTX | FBIO |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 113.9M |
| IPO Year | 2020 | N/A |
| Metric | NKTX | FBIO |
|---|---|---|
| Price | $2.09 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $13.25 | ★ $16.50 |
| AVG Volume (30 Days) | 708.2K | ★ 785.2K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $1.33 |
| 52 Week High | $2.74 | $4.53 |
| Indicator | NKTX | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 78.81 |
| Support Level | $1.79 | $4.02 |
| Resistance Level | $2.22 | $4.34 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 75.73 | 88.89 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.